Timo Minssen

Timo Minssen

Professor

ORCID: 0000-0002-3286-4888
26 - 50 ud af 63Pr. side: 25
Sortering: Titel

  1. Interview with Danish Radio (DR) on compulsory licensing issues

    Timo Minssen

    12/02/2021

    1 Mediebidrag

    Presse/medie

  2. Juridisk krig for milliarder

    Timo Minssen

    14/02/2011

    1 Mediebidrag

    Presse/medie

  3. Key takeaways from IAM’s 2020 Pharma and Biotech IP event

    Timo Minssen

    06/02/2020

    1 Mediebidrag

    Presse/medie

  4. LSPN Europe 2017: Broad had ‘no clue’ about CRISPR licensing in agriculture

    Timo Minssen

    07/12/2017

    1 Mediebidrag

    Presse/medie

  5. Locus licenses CRISPR tech to Janssen in potential $818m deal

    Timo Minssen

    09/01/2019

    1 Mediebidrag

    Presse/medie

  6. Los secretos comerciales, un obstáculo para la producción de una vacuna contra la Covid-19

    Timo Minssen

    14/08/2020

    1 Mediebidrag

    Presse/medie

  7. Medicinalindustri vil fortsat skjule oplysninger om forsøg

    Timo Minssen

    01/02/2018

    1 Mediebidrag

    Presse/medie

  8. Mixed views on Broad’s fate after EPO revokes CRISPR patent

    Timo Minssen

    18/01/2018

    1 Mediebidrag

    Presse/medie

  9. Novo anklages for patentmisbrug i USA

    Timo Minssen

    21/06/2013

    1 Mediebidrag

    Presse/medie

  10. Novo kaster millioner efter retsopgør med Kåre Schultz og Teva

    Timo Minssen & Karin Beukel

    17/01/2018

    1 Mediebidrag

    Presse/medie

  11. Novo på vej mod sejr i patentstrid

    Timo Minssen

    29/06/2016

    1 Mediebidrag

    Presse/medie

  12. Novo styrer mod overraskende sejr i patentkrig: Berlingske Business

    Timo Minssen

    29/06/2016

    1 Mediebidrag

    Presse/medie

  13. Novo vingeskudt i patentslagsmål: Berlingske Business

    Timo Minssen

    15/03/2016

    1 Mediebidrag

    Presse/medie

  14. Når man blander kunstig intelligens med biomedicin, så er juraen essential - Interview with CeBIL Director Timo Minssen

    Timo Minssen

    11/10/2018

    1 Mediebidrag

    Presse/medie

  15. Obama-forslag truer Novo

    Timo Minssen

    16/02/2011

    1 Mediebidrag

    Presse/medie

  16. On antibiotics, capital gains, China, America’s civil war, unicorns, ties - Letters to the editor

    Jonathan Darrow & Timo Minssen

    25/05/2019

    1 Mediebidrag

    Presse/medie

  17. Patentstrid fortsætter for Novo

    Timo Minssen

    05/08/2016

    1 Mediebidrag

    Presse/medie

  18. Pharma companies need data strategies more than ever following recent CJEU decisions

    Timo Minssen

    04/02/2020

    1 Mediebidrag

    Presse/medie

  19. Podcast-interview: Unlocking the full potential of Open Innovation in the Life Sciences through a classification system, see: https://www.ebe-biopharma.eu/wp-content/uploads/2018/01/EBE_Open-Innovation-Podcast-3.mp3

    Timo Minssen & Niclas Nilsson

    14/12/2017

    1 Mediebidrag

    Presse/medie

  20. Preparing for Antimicrobial Resistance: Vision and Social Science Mission of the INAMRSS Network

    Timo Minssen

    11/12/2020

    1 Mediebidrag

    Presse/medie

  21. Professor i sundhedsret: Er vi trygge ved at vaccineproduktion er ude af vores hænder?

    Timo Minssen

    19/03/2020

    1 Mediebidrag

    Presse/medie

  22. Professor: En coronavaccine skal udvikles hurtigt, men vi kan ikke slække for meget på sikkerheden

    Timo Minssen

    23/03/2020

    1 Mediebidrag

    Presse/medie

  23. Regulating digital health - 2020

    Timo Minssen

    01/04/2020

    1 Mediebidrag

    Presse/medie

  24. Russian patents grab deemed ‘act of war’

    Timo Minssen

    16/06/2022

    1 Mediebidrag

    Presse/medie

  25. SWEDEN’s Response to COVID-19: A tale of trust, recommendations, and odorous nudges

    Timo Minssen

    12/05/2020

    1 Mediebidrag

    Presse/medie

Forrige 1 2 3 Næste

ID: 16150437